Coverage, Formulary Restrictions, and Affordability of Sodium-Glucose Cotransporter 2 Inhibitors by US Insurance Plan Types.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Medical Association Country of Publication: United States NLM ID: 101769500 Publication Model: eCollection Cited Medium: Internet ISSN: 2689-0186 (Electronic) Linking ISSN: 26890186 NLM ISO Abbreviation: JAMA Health Forum
    • Publication Information:
      Original Publication: Chicago, IL : American Medical Association, [2020]-
    • Subject Terms:
      Diabetes Mellitus, Type 2*/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors*/economics ; Drug Costs* ; Insurance, Health*; Humans ; Blood Glucose ; Costs and Cost Analysis ; Cross-Sectional Studies ; Hypoglycemic Agents/economics ; Medicare ; United States
    • Abstract:
      This cross-sectional study evaluates the stipulations of coverage under commercial, health insurance exchange, Veterans Affairs, Medicare, Medicaid, or other insurance for canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
      Competing Interests: Conflict of Interest Disclosures: Dr Tummalapalli reported receiving personal fees from Bayer AG and grants from Scanwell Health outside the submitted work. Dr Lamprea Montealegre reported receiving research funding from Bayer outside the submitted work. Dr Warnock reported being employed by Bayer AG. Mr Green reported being employed by Clarivate Analytics (US) LLC. Dr Estrella reported receiving grants from Bayer AG and personal fees from Boehringer-Ingelheim outside the submitted work. Dr Ibrahim reported being Associate Editor for JAMA Health Forum. No other disclosures were reported.
      (Copyright 2021 Tummalapalli SL et al. JAMA Health Forum.)
    • References:
      Am J Manag Care. 2014 Apr;20(4):322-31. (PMID: 24884863)
      Diabetes Obes Metab. 2020 Dec;22(12):2364-2374. (PMID: 32744392)
      JAMA Netw Open. 2020 Oct 1;3(10):e2020969. (PMID: 33057641)
      JAMA Netw Open. 2021 Apr 1;4(4):e216139. (PMID: 33856475)
    • Grant Information:
      F32 DK122627 United States DK NIDDK NIH HHS
    • Accession Number:
      0 (Blood Glucose)
      0 (Hypoglycemic Agents)
      0 (Sodium-Glucose Transporter 2 Inhibitors)
    • Publication Date:
      Date Created: 20220817 Date Completed: 20231013 Latest Revision: 20231013
    • Publication Date:
      20231215
    • Accession Number:
      PMC8796944
    • Accession Number:
      10.1001/jamahealthforum.2021.4205
    • Accession Number:
      35977296